Cargando…

Rapidly and successful improvement of nail psoriasis with risankizumab

This clinical case demonstrates quick resolution of nail psoriasis in a patient treated with risankizumab, highlighting the role of IL‐23 in the pathogenesis of nail psoriasis.

Detalles Bibliográficos
Autores principales:	Orsini, Diego, Pacifico, Alessia, Iacovelli, Paolo, Frascione, Pasquale, De Simone, Paola, Assorgi, Chiara, Pigliacelli, Flavia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562652/ https://www.ncbi.nlm.nih.gov/pubmed/37822482 http://dx.doi.org/10.1002/ccr3.8035

Ejemplares similares

A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Risankizumab for psoriasis
Publicado: (2020)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Allergic contact dermatitis to dorzolamide and benzalkonium chloride
por: Orsini, Diego, et al.
Publicado: (2018)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
por: Al Muqrin, Abdullah Muqrin, et al.
Publicado: (2022)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
por: Barber, Cara, et al.
Publicado: (2022)

Facial Abrikosoff tumour: The role of the dermatologist during COVID‐19 pandemic
por: Orsini, Diego, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma
por: Glinos, George D., et al.
Publicado: (2021)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Successful treatment of a refractory pyoderma gangrenosum with risankizumab
por: Burgdorf, Birte, et al.
Publicado: (2020)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
por: Kołt-Kamińska, Marta, et al.
Publicado: (2023)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
por: Barber, Cara, et al.
Publicado: (2022)

Nail clipping in onychomycosis and comparison with normal nails and ungual psoriasis
por: Trevisan, Flávia, et al.
Publicado: (2019)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

Costo per responder di risankizumab e secukinumab nel trattamento della psoriasi a placche da moderata a grave in Italia
por: Gisondi, Paolo, et al.
Publicado: (2021)

Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
por: REPETTO, Federica, et al.
Publicado: (2022)

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
por: Khatri, Amit, et al.
Publicado: (2019)

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2021)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
por: Yu, Qianying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2kauls5meomq3ov9bh1htgnt1